The NHGRI Bioethics Core supports the NHGRI intramural research program by providing infrastructure and training related to the NHGRI Institutional Review Board (IRB), coordinating annual Responsible Conduct of Research educational sessions, moderating bioethics rounds at the clinical genetics case conference, and representing NHGRI within the Clinical Centers ethics consultation service and Ethics Committee. In addition, the Core is available to address emergent bioethics education and consultation needs for the DIR. The Bioethics Core is responsible for ensuring that NHGRI is compliant with the regulations, policies, and guidelines governing the ethical conduct of federally-funded human subjects research (e.g,. 45 CFR 46). This is especially relevant in the context of NIHs current plans to seek accreditation of its IRB program;the Core is responsible for ensuring that NHGRI policies and practices meet the standards set forth by the accrediting body. The Core provides the administrative infrastructure for the NHGRI IRB. In FY12, this involved maintaining a system of records for nearly 120 active NHGRI IRB-reviewed intramural research protocols, per 45 CFR 46.115 and the NIH Federal-Wide Assurance. This included processing of new protocol submissions, continuing and triennial reviews, terminations, amendments, adverse events, and deviations/violations. The Core continues to refine the electronic protocol submission and distribution application (PTMS) to streamline the IRB infrastructure, simplify the review process for investigators, and reduce the volume of paperwork associated with the process. The Core regularly consults with DIR investigators on the development and revisions of their protocols and consent forms for the IRB. This includes a formal pre-review process of all new protocol submissions as well as ad hoc guidance at any stage in the submission and review process. The Core advises investigators who have questions concerning regulations and procedures related to the submission and review of their protocols (for the NHGRI IRB as well as other IRBs to which they may need to submit their protocols), and synthesizes and disseminates new information regarding policy and procedural changes in the review/approval process.
|Bharti, Kapil; Rao, Mahendra; Hull, Sara Chandros et al. (2014) Developing cellular therapies for retinal degenerative diseases. Invest Ophthalmol Vis Sci 55:1191-202|
|Berkman, Benjamin E; Hull, Sara Chandros (2014) The "right not to know" in the genomic era: time to break from tradition? Am J Bioeth 14:28-31|
|Hull, Sara Chandros; Berkman, Benjamin E (2014) Grappling with genomic incidental findings in the clinical realm. Chest 145:226-30|
|Isasi, Rosario; Andrews, Peter W; Baltz, Jay M et al. (2014) Identifiability and privacy in pluripotent stem cell research. Cell Stem Cell 14:427-30|
|Abdul-Karim, Ruqayyah; Berkman, Benjamin E; Wendler, David et al. (2013) Disclosure of incidental findings from next-generation sequencing in pediatric genomic research. Pediatrics 131:564-71|
|Hull, Sara Chandros; Colloca, Luana; Avins, Andrew et al. (2013) Patients' attitudes about the use of placebo treatments: telephone survey. BMJ 347:f3757|